Literature DB >> 11484818

Development of muscle pathology in canine X-linked muscular dystrophy. II. Quantitative characterization of histopathological progression during postnatal skeletal muscle development.

F Cozzi1, M Cerletti, G C Luvoni, R Lombardo, P G Brambilla, S Faverzani, F Blasevich, F Cornelio, O Pozza, M Mora.   

Abstract

We have characterized the time course of muscle pathology development during the postnatal maturation of quadriceps and tibialis anterior muscle in dystrophic golden retriever dogs. We determined the percentages of degenerating, regenerating, calcium-positive, hypercontracted, albumin-positive, and C3 complement fraction-positive muscle fibers and the extent of connective tissue proliferation in animals from neonate to adult. Necrotic fibers increased from days 2 to 30, decreased at 60 days (to 0.8%) and increased in older animals to a stable level of around 2%. Hypercontracted fibers peaked at 15 days (19.1%) and declined to 3.7% in adults. Regenerating fibers were numerous at 15 and 30 days (10%), declined at 60 days to 4.7% and declined further in adults. Calcium- and albumin-positive fibers peaked at 30 days (6.5% and 13.8%, respectively) and then declined to around 3% and 5%, respectively, in older dogs. In dystrophic dogs, the extent of fibrosis was significantly greater on 15 days than in controls, but did not then increase with age. In carriers, calcium- and albumin-positive fibers always expressed dystrophin abnormally. Muscle damage occurs before completion of muscle maturation in dystrophic dogs. While necrosis and hypercontraction remain stable in adults, fiber regeneration declines to very low levels. In contrast to Duchenne muscular dystrophy, muscle fibrosis in the muscle studied does not increase with age.

Entities:  

Mesh:

Year:  2001        PMID: 11484818     DOI: 10.1007/s004010000308

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  10 in total

Review 1.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

2.  Suppression of muscle hypercontraction by mutations in the myosin heavy chain gene of Drosophila melanogaster.

Authors:  Upendra Nongthomba; Mark Cummins; Samantha Clark; Jim O Vigoreaux; John C Sparrow
Journal:  Genetics       Date:  2003-05       Impact factor: 4.562

3.  An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed.

Authors:  Bruce F Smith; Yongping Yue; Philip R Woods; Joe N Kornegay; Jin-Hong Shin; Regina R Williams; Dongsheng Duan
Journal:  Lab Invest       Date:  2010-08-16       Impact factor: 5.662

4.  miRNAs as serum biomarkers for Duchenne muscular dystrophy.

Authors:  Davide Cacchiarelli; Ivano Legnini; Julie Martone; Valentina Cazzella; Adele D'Amico; Enrico Bertini; Irene Bozzoni
Journal:  EMBO Mol Med       Date:  2011-03-21       Impact factor: 12.137

5.  Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin/utrophin double knockout mice.

Authors:  Dejia Li; Yongping Yue; Dongsheng Duan
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

6.  Increased microenvironment stiffness in damaged myofibers promotes myogenic progenitor cell proliferation.

Authors:  Frédéric Trensz; Fabrice Lucien; Vanessa Couture; Thomas Söllrald; Geneviève Drouin; André-Jean Rouleau; Michel Grandbois; Gregory Lacraz; Guillaume Grenier
Journal:  Skelet Muscle       Date:  2015-02-17       Impact factor: 4.912

7.  Motor physical therapy affects muscle collagen type I and decreases gait speed in dystrophin-deficient dogs.

Authors:  Thaís P Gaiad; Karla P C Araujo; Júlio C Serrão; Maria A Miglino; Carlos Eduardo Ambrósio
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

8.  Low intensity, high frequency vibration training to improve musculoskeletal function in a mouse model of Duchenne muscular dystrophy.

Authors:  Susan A Novotny; Tara L Mader; Angela G Greising; Angela S Lin; Robert E Guldberg; Gordon L Warren; Dawn A Lowe
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

Review 9.  Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy.

Authors:  Joe W McGreevy; Chady H Hakim; Mark A McIntosh; Dongsheng Duan
Journal:  Dis Model Mech       Date:  2015-03       Impact factor: 5.758

Review 10.  CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives.

Authors:  Guofang Chen; Tingyi Wei; Hui Yang; Guoling Li; Haisen Li
Journal:  Cells       Date:  2022-09-22       Impact factor: 7.666

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.